Jérôme Hert
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jérôme Hert.
Nature | 2009
Michael J. Keiser; Vincent Setola; John J. Irwin; Christian Laggner; Atheir I. Abbas; Sandra J. Hufeisen; Niels H. Jensen; Michael B. Kuijer; Roberto R. Capela de Matos; Thuy B. Tran; Ryan Whaley; Richard A. Glennon; Jérôme Hert; Kelan L. Thomas; Douglas D. Edwards; Brian K. Shoichet; Bryan L. Roth
Although drugs are intended to be selective, at least some bind to several physiological targets, explaining side effects and efficacy. Because many drug–target combinations exist, it would be useful to explore possible interactions computationally. Here we compared 3,665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands. Chemical similarities between drugs and ligand sets predicted thousands of unanticipated associations. Thirty were tested experimentally, including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor. Overall, 23 new drug–target associations were confirmed, five of which were potent (<100 nM). The physiological relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse. The chemical similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.
Journal of Chemical Information and Computer Sciences | 2004
Jérôme Hert; Peter Willett; David J. Wilton; Pierre Acklin; Kamal Azzaoui; Edgar Jacoby; Ansgar Schuffenhauer
Fingerprint-based similarity searching is widely used for virtual screening when only a single bioactive reference structure is available. This paper reviews three distinct ways of carrying out such searches when multiple bioactive reference structures are available: merging the individual fingerprints into a single combined fingerprint; applying data fusion to the similarity rankings resulting from individual similarity searches; and approximations to substructural analysis. Extended searches on the MDL Drug Data Report database suggest that fusing similarity scores is the most effective general approach, with the best individual results coming from the binary kernel discrimination technique.
Organic and Biomolecular Chemistry | 2004
Jérôme Hert; Peter Willett; David J. Wilton; Pierre Acklin; Kamal Azzaoui; Edgar Jacoby; Ansgar Schuffenhauer
This paper reports a detailed comparison of a range of different types of 2D fingerprints when used for similarity-based virtual screening with multiple reference structures. Experiments with the MDL Drug Data Report database demonstrate the effectiveness of fingerprints that encode circular substructure descriptors generated using the Morgan algorithm. These fingerprints are notably more effective than fingerprints based on a fragment dictionary, on hashing and on topological pharmacophores. The combination of these fingerprints with data fusion based on similarity scores provides both an effective and an efficient approach to virtual screening in lead-discovery programmes.
Nature Chemical Biology | 2009
Jérôme Hert; John J. Irwin; Christian Laggner; Michael J. Keiser; Brian K. Shoichet
In lead discovery, libraries of 106 molecules are screened for biological activity. Given the over 1060 drug-like molecules thought possible, such screens might never succeed. That they do, even occasionally, implies a biased selection of library molecules. Here a method is developed to quantify the bias in screening libraries towards biogenic molecules. With this approach, we consider what is missing from screening libraries and how they can be optimized.
Journal of Chemical Information and Modeling | 2006
Jérôme Hert; Peter Willett; David J. Wilton; Pierre Acklin; Kamal Azzaoui; Edgar Jacoby; Ansgar Schuffenhauer
Similarity searching using a single bioactive reference structure is a well-established technique for accessing chemical structure databases. This paper describes two extensions of the basic approach. First, we discuss the use of group fusion to combine the results of similarity searches when multiple reference structures are available. We demonstrate that this technique is notably more effective than conventional similarity searching in scaffold-hopping searches for structurally diverse sets of active molecules; conversely, the technique will do little to improve the search performance if the actives are structurally homogeneous. Second, we make the assumption that the nearest neighbors resulting from a similarity search, using a single bioactive reference structure, are also active and use this assumption to implement approximate forms of group fusion, substructural analysis, and binary kernel discrimination. This approach, called turbo similarity searching, is notably more effective than conventional similarity searching.
Journal of Chemical Information and Modeling | 2008
Jérôme Hert; Michael J. Keiser; John J. Irwin; Tudor I. Oprea; Brian K. Shoichet
The similarity of drug targets is typically measured using sequence or structural information. Here, we consider chemo-centric approaches that measure target similarity on the basis of their ligands, asking how chemoinformatics similarities differ from those derived bioinformatically, how stable the ligand networks are to changes in chemoinformatics metrics, and which network is the most reliable for prediction of pharmacology. We calculated the similarities between hundreds of drug targets and their ligands and mapped the relationship between them in a formal network. Bioinformatics networks were based on the BLAST similarity between sequences, while chemoinformatics networks were based on the ligand-set similarities calculated with either the Similarity Ensemble Approach (SEA) or a method derived from Bayesian statistics. By multiple criteria, bioinformatics and chemoinformatics networks differed substantially, and only occasionally did a high sequence similarity correspond to a high ligand-set similarity. In contrast, the chemoinformatics networks were stable to the method used to calculate the ligand-set similarities and to the chemical representation of the ligands. Also, the chemoinformatics networks were more natural and more organized, by network theory, than their bioinformatics counterparts: ligand-based networks were found to be small-world and broad-scale.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A. Crews; John J. Irwin; Eugen Lounkine; Lawrence J. Marnett; Bryan L. Roth; Brian K. Shoichet
Notwithstanding their key roles in therapy and as biological probes, 7% of approved drugs are purported to have no known primary target, and up to 18% lack a well-defined mechanism of action. Using a chemoinformatics approach, we sought to “de-orphanize” drugs that lack primary targets. Surprisingly, targets could be easily predicted for many: Whereas these targets were not known to us nor to the common databases, most could be confirmed by literature search, leaving only 13 Food and Drug Administration—approved drugs with unknown targets; the number of drugs without molecular targets likely is far fewer than reported. The number of worldwide drugs without reasonable molecular targets similarly dropped, from 352 (25%) to 44 (4%). Nevertheless, there remained at least seven drugs for which reasonable mechanism-of-action targets were unknown but could be predicted, including the antitussives clemastine, cloperastine, and nepinalone; the antiemetic benzquinamide; the muscle relaxant cyclobenzaprine; the analgesic nefopam; and the immunomodulator lobenzarit. For each, predicted targets were confirmed experimentally, with affinities within their physiological concentration ranges. Turning this question on its head, we next asked which drugs were specific enough to act as chemical probes. Over 100 drugs met the standard criteria for probes, and 40 did so by more stringent criteria. A chemical information approach to drug-target association can guide therapeutic development and reveal applications to probe biology, a focus of much current interest.
Journal of Medicinal Chemistry | 2016
Bernd Kuhn; Wolfgang Guba; Jérôme Hert; David W. Banner; Caterina Bissantz; Simona M. Ceccarelli; Wolfgang Haap; Matthias Körner; Andreas Kuglstatter; Christian Lerner; Patrizio Mattei; Werner Neidhart; Emmanuel Pinard; Markus G. Rudolph; Tanja Schulz-Gasch; Thomas Johannes Woltering; Martin Stahl
We present a series of small molecule drug discovery case studies where computational methods were prospectively employed to impact Roche research projects, with the aim of highlighting those methods that provide real added value. Our brief accounts encompass a broad range of methods and techniques applied to a variety of enzymes and receptors. Most of these are based on judicious application of knowledge about molecular conformations and interactions: filling of lipophilic pockets to gain affinity or selectivity, addition of polar substituents, scaffold hopping, transfer of SAR, conformation analysis, and molecular overlays. A case study of sequence-driven focused screening is presented to illustrate how appropriate preprocessing of information enables effective exploitation of prior knowledge. We conclude that qualitative statements enabling chemists to focus on promising regions of chemical space are often more impactful than quantitative prediction.
Journal of Medicinal Chemistry | 2017
Bernd Kuhn; Michal Tichý; Lingle Wang; Shaughnessy Robinson; Rainer E. Martin; Andreas Kuglstatter; Jörg Benz; Maude Giroud; Tanja Schirmeister; Robert Abel; François Diederich; Jérôme Hert
Improving the binding affinity of a chemical series by systematically probing one of its exit vectors is a medicinal chemistry activity that can benefit from molecular modeling input. Herein, we compare the effectiveness of four approaches in prioritizing building blocks with better potency: selection by a medicinal chemist, manual modeling, docking followed by manual filtering, and free energy calculations (FEP). Our study focused on identifying novel substituents for the apolar S2 pocket of cathepsin L and was conducted entirely in a prospective manner with synthesis and activity determination of 36 novel compounds. We found that FEP selected compounds with improved affinity for 8 out of 10 picks compared to 1 out of 10 for the other approaches. From this result and other additional analyses, we conclude that FEP can be a useful approach to guide this type of medicinal chemistry optimization once it has been validated for the system under consideration.
ChemMedChem | 2013
Christin Schärfer; Tanja Schulz-Gasch; Jérôme Hert; Lennart Heinzerling; B. Schulz; Therese Inhester; Martin Stahl; Matthias Rarey
The generation of sets of low‐energy conformations for a given molecule is a central task in drug design. Herein we present a new conformation generator called CONFECT that builds on our previously published library of torsion patterns. Conformations are generated as well as ranked by means of normalized frequency distributions derived from the Cambridge Structural Database (CSD). Following an incremental construction approach, conformations are selected from a systematic enumeration within energetic boundaries. The new tool is benchmarked in several different ways, indicating that it allows the efficient generation of high‐quality conformation ensembles. These ensembles are smaller than those produced by state‐of‐the‐art tools, yet they effectively cover conformational space.